Abiopharma

🔍 Dunbar David A. (Director)

Company: STANDEX INTERNATIONAL CORP/DE/ (SXI)

Report Date: 2026-08-21

Detailed Transactions and Holdings:

• Acquired 4,441 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 5,870.98 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 1,644 shares of Common Stock at $310.28 per share (Direct)
  Date: 2026-08-21 | Code: F | equity_swap_involved: 0 | shares_owned_after: 4,226.98 | transaction_form_type: 4 | Footnotes: F2
• Acquired 7,208 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 11,434.98 | transaction_form_type: 4 | Footnotes: F3, F3
• Sold 2,837 shares of Common Stock at $310.28 per share (Direct)
  Date: 2026-08-21 | Code: F | equity_swap_involved: 0 | shares_owned_after: 8,597.98 | transaction_form_type: 4 | Footnotes: F2
• Acquired 2,300 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 10,897.98 | transaction_form_type: 4 | Footnotes: F4, F4
• Sold 851 shares of Common Stock at $310.28 per share (Direct)
  Date: 2026-08-21 | Code: F | equity_swap_involved: 0 | shares_owned_after: 10,046.98 | transaction_form_type: 4 | Footnotes: F2
• Acquired 2,076 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 12,122.98 | transaction_form_type: 4 | Footnotes: F4, F4
• Sold 817 shares of Common Stock at $310.28 per share (Direct)
  Date: 2026-08-21 | Code: F | equity_swap_involved: 0 | shares_owned_after: 11,305.98 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: H | nature_of_ownership: Trustee of Trust | shares_owned_after: 88,973.00
• Sold 4,441 shares of Phantom Stock Units at $106.1 per share (Derivative)
  Date: 2026-08-21 | Code: M | Expires: 2026-08-23 | Exercise: 2026-08-23 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 7,208 shares of Phantom Stock Units (Derivative)
  Date: 2026-08-21 | Code: M | Expires: 2026-08-23 | Exercise: 2026-08-23 | equity_swap_involved: 0 | shares_owned_after: 3,393.00 | transaction_form_type: 4 | Footnotes: F3, F3, F3
• Sold 3,393 shares of Phantom Stock Units (Derivative)
  Date: 2026-08-21 | Code: D | Expires: 2026-08-23 | Exercise: 2026-08-23 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F5, F5, F5
• Sold 2,300 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,300.00 | transaction_form_type: 4 | Footnotes: F4, F4, F4, F4, F4
• Sold 2,076 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 4,152.00 | transaction_form_type: 4 | Footnotes: F4, F4, F4, F4, F4
• Acquired 2,285 shares of Phantom Stock Units (Derivative)
  Date: 2026-08-23 | Code: A | Expires: 2029-08-23 | Exercise: 2029-08-23 | equity_swap_involved: 0 | shares_owned_after: 2,285.00 | transaction_form_type: 4 | Footnotes: F6, F6, F6
• Acquired 7,156 shares of Phantom Stock Units (Derivative)
  Date: 2026-08-23 | Code: A | Expires: 2029-08-23 | Exercise: 2029-08-23 | equity_swap_involved: 0 | shares_owned_after: 7,156.00 | transaction_form_type: 4 | Footnotes: F7, F7, F7
• Acquired 4,770 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-23 | Code: A | equity_swap_involved: 0 | shares_owned_after: 4,770.00 | transaction_form_type: 4 | Footnotes: F8, F8, F8, F8, F8
• Acquired 32,600 shares of Stock Option at $341.31 per share (Derivative)
  Date: 2026-08-23 | Code: A | equity_swap_involved: 0 | shares_owned_after: 32,600.00 | transaction_form_type: 4 | Footnotes: F9, F9, F9, F9

Footnotes:

• F1: Vesting of Phantom Stock pursuant to Company's Management Stock Purchase Plan.
• F2: Shares sold to pay taxes on vesting of previously issued restricted stock and/or performance share units.
• F3: Vesting of Phantom Stock pursuant to the Company's 2018 Omnibus Incentive Plan. Actual achievement, which could have ranged from 0% to 250% of the award, was 68%. The transaction reported herein is the actual number of shares vesting pursuant thereto.
• F4: Vesting of Restricted Stock Units pursuant to the Company's 2018 Omnibus Incentive Plan.
• F5: Vesting of Phantom Stock pursuant to the Company's 2018 Omnibus Incentive Plan. Actual achievement, which could have ranged from 0% to 250% of the award, was 68%. Phantom Stock Units were granted at 100% achievement, so this transaction reflects the disposition of shares to accurately reflect the vesting.
• F6: Contingent Purchase of Phantom Stock of the Company pursuant to the Management Stock Purchase Plan component of the 2018 Omnibus Incentive Plan vesting three years after the date of purchase in the form of Common Stock.
• F7: Award of Performance Share Units pursuant to the 2018 Omnibus Incentive Plan of the Company. These shares cliff vest at the end of a three year performance period with the ultimate number of shares ranging from 0 to 250% of the award based on achievement against Company performance metrics of the three year period.
• F8: Grant of Restricted Stock Units pursuant to the 2018 Omnibus Incentive Plan of the Company which vests one-third per year on each anniversary of the date of the award.
• F9: Premium Priced Stock Option with exercise price 10% above the closing market price on the date of grant. Option vests 25% per year on each anniversary of the date of the award for four years. This option expires ten years from the date of grant.